The global HIV antivirals market has witnessed a significant surge, with sales reaching an impressive USD 30.6 billion as of 2022, according to recent reports. Projections indicate a promising trajectory, with the market poised to achieve an estimated value of USD 47.0 billion by the conclusion of 2032. This reflects a steady Compound Annual Growth Rate (CAGR) of 4.4%.
This notable growth underscores advancements in pharmaceutical research and development and demonstrates a global commitment to enhancing healthcare solutions for individuals affected by HIV/AIDS. The increasing demand for HIV antivirals is driven by greater access to effective HIV diagnosis, treatment, prevention, and care, making HIV infection a manageable chronic health condition similar to cancer and tuberculosis. This advancement enables people living with HIV to lead healthy and long lives.
Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-15095
The HIV antivirals market is set to expand further due to rising awareness about HIV causes, symptoms, and available treatment options. Various awareness programs organized by the U.S. Department of Health & Human Services aim to educate the public about HIV and its testing.
For example, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) observes May 18th as HIV Vaccine Awareness Day. This day is dedicated to showing gratitude towards community members, volunteers, healthcare professionals, and scientists working together to find a safe and effective preventive HIV vaccine.
As the global community continues to prioritize HIV research and awareness, the future of the HIV antivirals market looks bright, promising better healthcare outcomes for individuals worldwide.
Key Takeaways from Market Study:
- Because of their ability to increase adherence to an HIV treatment regimen, fixed-dose combinations (FDCs) owned more than 83.2% of the market value in 2021.
- Hospital pharmacies are the dominant sales channel for HIV antivirals, accounting for over 53.4% of the market in 2021, and are expected to increase at a CAGR of 4.5% over the next decade.
- In 2021, the United States dominated the North American HIV antivirals market, with a total market share of around 96.8%.
- Because of the increasing number of HIV patients in the country, India is likely to lead the growth in the South Asian market.
“With increasing awareness among the people about HIV causes and symptoms, the HIV antivirals market is set witness positive growth during the forecast period. Hence, key players are developing anti-HIC drugs vaccines to increase their revenue,” says an analyst of Future Market Insights.
Request Customization of the Report: https://www.futuremarketinsights.com/customization-available/rep-gb-15095
Competitive Landscape:
Key players in the HIV antivirals market are focusing on collaborations and securing FDA approvals as primary strategies to expand their business.
These strategies will help market players like Theratechnologies and AbbVie enhance their product portfolios and increase market penetration, thereby boosting their revenue share in the global market.
For example:
- In December 2021, Theratechnologies submitted a supplemental biologics license application to the FDA to advance the development of IV Push Trogarzo® for patients living with HIV.
- In March 2020, AbbVie announced a partnership with international authorities to test the efficacy of HIV medicines in treating COVID-19.
Key Companies Profiled:
- ViiV Healthcare
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Johnson & Johnson
- Genetech, Inc.
- Teva Pharmaceutical Industries Ltd.
- AbbVie
- Cipla
- Pfizer Inc.
- Mylan N.V.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Macleods Pharmaceuticals Ltd
- Emcure Pharmaceuticals Limited
- Aspen Pharmacare Limited
- Lupin Ltd.
- Sun Pharmaceutical Industries Ltd.
- Theratechnologies Inc.
- Strides Arcolab Limited
- Hetero labs limited
- Laurus Laboratories Ltd
A Full Report on Market: https://www.futuremarketinsights.com/checkout/15095
Key Market Segments Covered in HIV Antivirals Market Research
By Product:
- Fixed Dose Combinations (FDCs)
- Integrase Strand Transfer Inhibitors (INSTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Entry Inhibitors – CCR5 co-receptor antagonist
- Protease Inhibitors (PIs)
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
